No doubt strides have been made in giving more people access to anti-retroviral drugs. But will the progress continue? Jim Clancy put that question to Emi Maclean, Director of the Doctors Without Borders Access Campaign.
Eric Goemaere hopes the patent pool will work out so he doesn't have to watch his patients in Khayelitsha die. In the U.S. HIV patients have a 69-year life expectancy. But his patients in Khayelitsha are running out of options after only 8 years on therapy. "I don't accept the principle of double standards," he says. "If it's possible to get 69 years of life in the U.S., it should be possible to get something comparable in South Africa."
Many global health advocates worry that the success of PEPfAR — an initiative that has consistently enjoyed broad bipartisan support — may be jeopardized by harsh economic realities and shifting political priorities. After five straight years of funding hikes and public-health victories, the slowdown has AIDS advocates scratching their heads: Why would the Obama Administration back off from the one universally popular program inherited from Bush?